# Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects

> **NCT02176512** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBR 277 SE and HCTZ
- **DRUG:** BIBR 277 SE
- **DRUG:** HCTZ

## Key facts

- **NCT ID:** NCT02176512
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 1998-10
- **Final completion:** —
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02176512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02176512, "Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02176512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*